Skip to Content

Virtual Diagnosis?

September 1, 2000

The AIDS virus’s ability to quickly mutate and become resistant to new drugs makes it difficult for doctors to choose medications that will work. Researchers at Virco Group in Oxford, England, have created a new tool to give doctors better information about viral drug resistance, allowing them to design effective therapies. Called Virtual Phenotype, the analysis takes the genetic code of a patient’s HIV strain and predicts the drugs it will be resistant to. The system, one of the earliest examples of pharmacogenomics in action, reportedly provides the first quantitative analysis of viral drug resistance. The analysis is quicker than actual phenotype testing, which involves growing virus and screening it with drugs, and costs up to three times less. Virco is developing similar databases for cancer and hepatitis B.

Keep Reading

Most Popular

This startup wants to copy you into an embryo for organ harvesting

With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.

VR is as good as psychedelics at helping people reach transcendence

On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.